<DOC>
	<DOCNO>NCT02397707</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( PK ) , safety , tolerability single dose GS-9857 adult normal impaired hepatic function . Adults healthy control group match adult impaired hepatic function gender , age ( ± 10 year ) , body mass index ( ± 15 % ) .</brief_summary>
	<brief_title>Pharmacokinetics GS-9857 Adults With Normal Hepatic Function Moderate Severe Hepatic Impairment</brief_title>
	<detailed_description />
	<criteria>All individual : Screening laboratory value within defined threshold group Use two effective contraception method female childbearing potential sexually active male For individual moderate hepatic impairment : Diagnosis chronic ( &gt; 6 month ) hepatic impairment Score ChildPughTurcotte ( CPT ) scale 79 screening ( Child Pugh Class B ) . For individual severe hepatic impairment : Diagnosis chronic ( &gt; 6 month ) hepatic impairment Score CPT scale 1015 screening ( Child Pugh Class C ) For individual normal hepatic function : Hepatitis C Virus ( HCV ) antibody hepatitis B surface antigen negative All individual : Pregnant nursing female male pregnant female partner HIV infection History clinically significant illness medical disorder may interfere individual 's treatment , assessment compliance protocol For individual moderate severe hepatic impairment : Active HCV infection Current hepatic encephalopathy Variceal bleeding last 6 month unless band Prior placement portosystemic shunt History hepatorenal hepatopulmonary syndrome Spontaneous bacterial peritonitis currently within last 6 month Hospitalization within last 2 month relate cirrhosis Confirmed hypotension Suspicion hepatocellular carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>